We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
POMBILITI (Amicus Therapeutics Pty Ltd)
Product name
POMBILITI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
191 (255 working days)
Active ingredients
cipaglucosidase alfa
Registration type
NCE/ NBE
Indication
POMBILITI (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with lateonset Pompe disease (acid α-glucosidase [GAA] deficiency).